Spahn H, Knauf H, Mutschler E
Pharmakologisches Institut für Naturwissenschaftler der Johann Wolfgang Goethe-Universität Frankfurt/Main, FRG.
Eur J Clin Pharmacol. 1990;39(4):345-8. doi: 10.1007/BF00315407.
The pharmacokinetics of 20 mg torasemide i.v. has been studied in 7 healthy controls and 9 patients with varying degrees of renal impairment. Torasemide had a t1/2 of about 4h which was independent of kidney function, as the nonrenal clearance of torasemide was 3-times greater than its renal clearance. The active metabolite M 1 and the main metabolite M 5 were accumulated in chronic renal failure. In contrast to liver function, therefore, kidney failure does not have an important effect on the pharmacokinetics of torasemide.
已在7名健康对照者和9名不同程度肾功能损害患者中研究了静脉注射20毫克托拉塞米的药代动力学。托拉塞米的半衰期约为4小时，这与肾功能无关，因为托拉塞米的非肾清除率是其肾清除率的3倍。活性代谢物M1和主要代谢物M5在慢性肾衰竭中会蓄积。因此，与肝功能不同，肾衰竭对托拉塞米的药代动力学没有重要影响。
